BioVie Inc.

News & Events

Press Releases

In The Media

1. BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

   GlobeNewswire MAY 15, 2025 8:00 AM EDT
   Despite growing recognition of long COVID as a serious condition, diagnosed patients have no appr...
   READ ARTICLE

2. BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

   GlobeNewswire MAY 14, 2025 7:30 AM EDT
   CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie&#...
   READ ARTICLE

3. BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

   GlobeNewswire MAY 7, 2025 8:00 AM EDT
   CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie&#...
   READ ARTICLE

4. BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketin...
   READ ARTICLE

5. BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

   GlobeNewswire APR 30, 2025 9:00 PM EDT
   NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recogn...
   READ ARTICLE

6. BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

   GlobeNewswire APR 16, 2025 8:00 AM EDT
   SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezis...
   READ ARTICLE

7. ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions Survive Motions to Dismiss

   GlobeNewswire APR 8, 2025 8:56 AM EDT
   PHILADELPHIA, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM) ...
   READ ARTICLE

8. ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions Survive Motions to Dismiss

   GlobeNewswire APR 7, 2025 7:31 AM EDT
   PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM) ...
   READ ARTICLE

9. SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions Inc. (NASDAQ: MSS)

   GlobeNewswire APR 4, 2025 8:34 AM EDT
   PHILADELPHIA, April 04, 2025 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (NASDAQ: ARQQ) Class ...
   READ ARTICLE

10. BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

    GlobeNewswire MAR 27, 2025 8:00 AM EDT
    CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie...
    READ ARTICLE